RxDoctor Payments Data

Maulik Trivedi, MD

Psychiatry · Wesley Chapel, FLNPI 1134115355

Payments from drug & device makers

$660in general payments, 2019–2025

Across 15 payments — averaging $43.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuronetics, Inc.$136
  • Corium, LLC$133
  • Neos Therapeutics, LP$124
  • Otsuka America Pharmaceutical, Inc.$122
  • AbbVie$35
  • Supernus Pharmaceuticals, Inc.$31
  • plus $79 from 3 others

What the payments were for

  • Food & beverage$660100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$660 in reported general payments places this provider in the 55th percentile of 2,059 psychiatry providers in Florida.

See all psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$39,717
Medicare patients
99
Services billed
753

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole13$21,007
VyvanseLisdexamfetamine Dimesylate55$20,644
Lisdexamfetamine Dimesylate89$20,064
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine129$5,418
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine202$4,286
Aripiprazole61$2,689
Prazosin Hcl173$2,228
Duloxetine Hcl144$2,084
Desvenlafaxine Succinate ErDesvenlafaxine Succinate45$1,683
Mirtazapine97$1,484
Fluvoxamine Maleate47$1,325
Methylphenidate Hcl61$1,090
Bupropion XlBupropion Hcl94$1,045
Guanfacine Hcl ErGuanfacine Hcl71$943
Trazodone Hcl152$943

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$122$21,00713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,059 psychiatry providers in Florida.

Other psychiatry in Wesley Chapel

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →